Status:
COMPLETED
Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
This study will demonstrate the bioequivalence of metformin after single dose administration of sitagliptin/metformin 50/500 mg fixed dose combination (FDC) tablet and concomitant administration of si...
Eligibility Criteria
Inclusion
- is in good health
- is a nonsmoker
- is willing to follow all study guidelines
Exclusion
- has or has a history of any illness or condition that might confound the results of the study or make participation unsafe for the participant
- is a nursing mother
- is unwilling to consume the required high-fat breakfast
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT00929201
Start Date
January 1 2008
End Date
May 1 2008
Last Update
August 13 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.